Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
BridgeBio announced a voluntary agreement with the U.S. government to expand Medicaid access to its marketed medicine (Attruby) and lower drug costs, with the company expecting to avoid future pricing mandates. This is a material strategic and regulatory agreement affecting the company's commercial operations and pricing framework, but it does not fit neatly into the specific event categories (not M&A, not a restatement, not a covenant breach, not litigation). The agreement is operational and regulatory in nature, affecting market access and pricing policy going forward.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-08-31
Item 5.07
Helix Energy Solutions shareholders voted on August 31, 2026 at a special meeting and approved 12 proposals related to the all-stock merger with Hornbeck Offshore Services, including approval of the merger itself, conversion to Delaware corporation, and various charter provisions. The final voting results were certified by an independent inspector of election.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-31
Item 5.02
Jessica M. Fischer, Chief Financial Officer of Charter Communications, resigned effective October 15, 2026, to pursue another professional opportunity. Kevin D. Howard was appointed as Interim CFO.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 94%
filed 2026-08-31
Item 1.01
Cenntro Inc. entered into securities purchase agreements to issue up to 12.8 million shares of common stock at $3.773 per share for approximately $48.3 million in gross proceeds in a private placement exempt under Section 4(a)(2) and Regulation S. The issuance represents 20% or more of outstanding common stock and is conducted under Nasdaq Listing Rule 5635(d).
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-31
Item 8.01
The filing discloses material progress toward completion of a merger with Eli Lilly and Company. The Hart-Scott-Rodino antitrust waiting period expired on August 28, 2026, and regulatory clearances from the UK Competition and Markets Authority and Australian Competition and Consumer Commission have been obtained or are imminent. This represents a significant milestone in the consummation of a material acquisition that would result in AtaiBeckley becoming a wholly owned subsidiary of Eli Lilly.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-31
EX-99.4
Elevra Lithium disclosed FY26 full year financial results on 28 August 2026, reporting revenue of US$202 million (up 39% year-over-year), underlying EBITDA of US$14 million (a US$57 million improvement), and profit after tax of US$44 million.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-31
Item 7.01
Wendy Reynolds-Dobbs was appointed to serve as Senior Vice President & Chief Human Resources Officer, effective September 14, 2026. This is a named executive appointment to a C-suite role. While the filing also mentions Jed Milstein's transition out of the same role, the principal disclosed action centers on Reynolds-Dobbs taking the position, making this an exec_appointment rather than a departure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
Alvotech announced FDA acceptance for review of a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio for subcutaneous administration. This is a material regulatory milestone in the company's biosimilar development pipeline—FDA acceptance for review is a significant step toward potential market approval. While not a discrete M&A event, covenant breach, or other specifically-named category, this regulatory advancement is clearly operational and strategic, affecting investor assessment of the company's pipeline progress and commercial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
This press release announces the signing of a binding offtake agreement with LG Energy Solution for 8,000 metric tonnes per year of battery-quality lithium carbonate over 10 years for the South West Arkansas Project. Combined with the previously announced Trafigura agreement, this secures approximately 90% of the targeted offtake volume and is explicitly described as "another major milestone in the development of the SWA Project" and critical to supporting project financing and a Final Investment Decision. While this is a material commercial contract that advances the project toward FID and construction, it does not fit the specific categories of M&A activity, debt issuance, or other named event types—it is a strategic operational/commercial milestone for a development-stage project.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-31
EX-99.1
B2Gold reports a fatal workplace incident at its Masbate Gold Project in the Philippines on August 28, 2026, involving a pipe burst during scheduled maintenance at the Water Treatment Plant. While the company states mining and processing activities continue uninterrupted, a fatality at an operating mine is a material operational and safety event that would affect a reasonable investor's assessment of the company's operational risk, safety culture, and potential regulatory or legal consequences. This does not fit the specific categories of workforce_reduction (which addresses planned restructuring), material_litigation (no lawsuit disclosed), or legal_other (no regulatory action yet disclosed), but is clearly a material operational incident requiring disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-31
Item 1.01
Sono Group agreed to issue and sell 283,500 Ordinary Shares (19.9% of outstanding shares) to private purchasers at market price pursuant to an effective Form S-3 registration statement, representing a material dilutive equity issuance typical of a registered direct offering.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-31
Item 8.01
Sono Group N.V. entered into a non-binding letter of intent for a business combination with Sports One, contemplating a complete pivot from digital asset treasury business to sports franchise ownership and sports intelligence operations, with the combined entity to be renamed Sports One and Sports One equityholders owning a super-majority.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-31
EX-99.1
The press release announces the appointment of Chris Benecchi as Chief Operating Officer of Inventiva, effective August 31, 2026. This is a clear executive appointment of a named officer to a C-suite role. The appointment is material because it occurs at a critical juncture—as the company approaches Phase 3 topline results for its lead candidate lanifibranor (expected Q4 2026) and prepares for potential commercialization in 2028—and Benecchi brings 30 years of biopharmaceutical leadership with direct experience in launch readiness and commercial operations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 85%
filed 2026-08-31
Item 7.01
Wynn Resorts filed an 8-K under Item 7.01 (Regulation FD Disclosure) to furnish the interim report of its 72%-owned subsidiary Wynn Macau Limited for the six months ended June 30, 2026. The interim report constitutes interim financial results for a material subsidiary, which is a standard earnings disclosure. While technically a Regulation FD disclosure rather than a press release, the substance is the public dissemination of interim financial results for a significant operating entity.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-31
EX-99.1
The exhibit announces the departure of Claire M. C. Kennedy from Alamos Gold's Board of Directors, effective August 31, 2026, due to her appointment as Consul General of Canada in Chicago. As a board member and Chair of the Audit Committee since November 2015, her departure is a material governance event requiring disclosure under Item 5.02 of Form 8-K (or equivalent 6-K disclosure). The loss of an audit committee chair is material to investors assessing board oversight and financial controls.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-31
EX-99.1
Gilat announced a $100 million private placement of convertible notes to Israeli institutional investors, convertible into ordinary shares at $16.00 per share (60% premium to the August 28, 2026 closing price of $9.94). The notes are senior unsecured, bear 3.75% interest, and mature September 1, 2031. This is a material dilutive issuance of equity-linked securities raising capital for general corporate purposes and technology investments, with conversion mechanics that create shareholder dilution upon conversion or redemption.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-31
EX-99.1
RedHill divested its 70% stake in Talicia to Apotex for $18 million upfront plus up to $35 million in milestone payments. This is a material disposition of a significant asset that generates immediate liquidity and represents a strategic repositioning of the company's commercial business. The transaction is explicitly described as "a pivotal milestone" and "a major step in RedHill's strategic roadmap," directly affecting the company's asset base and capital structure.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-31
EX-99
This is a press release disclosing BioLineRx's unaudited financial results for the quarter ended June 30, 2026, including revenues, operating expenses, net loss, and cash position. The exhibit includes condensed consolidated interim financial statements (balance sheet, income statement, cash flows, and changes in equity) and a corporate update on clinical trial progress for GLIX1 and motixafortide. The financial results and clinical developments would materially affect a reasonable investor's assessment of the company's progress and financial condition.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-31
BioLineRx entered into a securities purchase agreement on August 27, 2026, to sell 480,696 ADSs, pre-funded warrants to purchase 868,225 ADSs, and unregistered warrants to purchase 2,023,382 ADSs in a registered direct offering and concurrent private placement. The unregistered warrants component and the private placement structure are characteristic of a dilutive equity issuance. Aggregate gross proceeds are approximately $3.75 million, with the company intending to use net proceeds for R&D and working capital.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-08-31
EX-99.1
This exhibit is a formal Compensation Policy for Executive Officers of Gilat Satellite Networks Ltd., adopted pursuant to the Companies Law 5759–1999. It comprehensively sets forth terms of service and compensation for Executive Officers, including base salary caps (NIS 130,000–170,000 for CEO/Chairman; NIS 90,000–120,000 for other executives), cash bonus structures, equity-based compensation vesting requirements, fringe benefits, and separation arrangements. The policy explicitly states it applies to "terms of service and compensation of Executive Officers which will be approved for payment after the date on which this Executive Compensation Policy was approved by the shareholders of the Company," indicating shareholder approval of these compensatory arrangements. This is a material governance disclosure affecting executive compensation terms.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-08-31
EX-99.1
The exhibit announces the appointment of Yoav Har-Even as Chairperson of the Board of Directors, effective immediately. While the prior Chairperson Amichai Steimberg stepped down, the principal disclosed action is Har-Even's appointment to the chair role. His extensive background as former President & CEO of Rafael Advanced Defense Systems and retired IDF Major General, combined with the Board's stated rationale that his appointment "reflects the strategic weight defense and security now carry for Innoviz," makes this a material governance change affecting board leadership at a public company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-08-31
Item 5.02
The filing discloses the departure of Mark Grant as President and Chief Executive Officer effective August 31, 2026, following execution of a separation agreement. While the Item also includes appointments of Josh Hexter as Interim CEO and Rami Aviram as CFO, the principal disclosed action centers on Grant's departure from the top executive role. The departure of a CEO is material to investors' assessment of the company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-31
Item 5.02
Scott Metzger resigned effective immediately as a member of the Board of Directors and the Compensation Committee. This is a clear departure event. The filing explicitly states the resignation is not due to disagreement, which is a standard protective disclosure but does not negate the materiality of a board member's departure. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-31
NaaS Technology entered into a Securities Purchase Agreement on August 28, 2026, to issue 24,024,022,400 Class A Ordinary Shares (7,507,507 ADSs) plus warrants to purchase an additional 22,880,022,400 Class A Ordinary Shares for US$25,000,000 in a private placement. The shares were issued without registration under the Securities Act in reliance on Regulation S and Regulation D, and bear restrictive legends. This is a classic dilutive private placement that materially increases share count and dilutes existing shareholders, particularly given the substantial number of shares issued and the related-party nature of the transaction involving the controlling shareholder Newlink.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-08-31
Item 1.02
T3 Defense Inc. executed a Cancellation Agreement on August 28, 2026, terminating a material acquisition agreement for a 60% equity stake in Project 35 Ltd. that had been previously disclosed on July 9, 2026. The termination involved return of 168,479 shares and a $1.25 million note, with both parties released from all liabilities, representing a material reversal of a change of control event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-31
Item 8.01
T3 Defense Inc. issued 1,344,969 shares through multiple mechanisms including Form S-8 registration, conversion of Series B Convertible Preferred Shares, and exercise of warrants, increasing outstanding shares by 81% from 1,663,806 to 3,008,775 shares. This represents material dilution to existing shareholders.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-08-31
EX-99
Mr. Sashidhar Jagdishan, the Managing Director & Chief Executive Officer (MD&CEO) of HDFC Bank, has conveyed his decision to not seek re-appointment and will retire effective October 26, 2026. The departure of a CEO is a material executive change that would affect a reasonable investor's assessment of the registrant's leadership and continuity.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-08-31
Item 1.01
BioMarin entered into a binding term sheet with Ascendis Pharma A/S on August 30, 2026, granting a non-exclusive, worldwide, royalty-bearing license to BioMarin's patents covering TransCon CNP (Yuviwel) for all indications including achondroplasia. The agreement resolves all pending patent litigation globally and provides for royalty payments of 20% of U.S. net sales and 18% of EU/Brazil/South Korea net sales until May 2030.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
Honda and Nissan have concluded a joint development agreement to standardize electronic control units (ECUs) and software for next-generation software-defined vehicles (SDVs), with planned application from fiscal year 2029 onward. This is a material strategic partnership in a core technology domain (vehicle software and electrification) that will affect Honda's product development, R&D efficiency, and competitive positioning, though the registrant notes no anticipated material impact on consolidated financial results for FY2027. The event is operational and strategic rather than fitting a discrete category like M&A, debt issuance, or executive change.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-31
Item 5.07
This is a clear disclosure of shareholder vote results from SemiLEDs' 2026 Annual Meeting held on August 28, 2026. The filing reports voting outcomes on two proposals: (1) election of five directors (Trung T. Doan, Walter Michael Gough, Dr. Edward Hsieh, Scott R. Simplot, and Dr. Chris Chang Yu) with specific vote tallies for each candidate, and (2) ratification of DLEE Accountancy, Inc. as independent auditor. This is a quintessential Item 5.07 disclosure of shareholder meeting results, which is material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-08-31
Item 1.01
Aon plc entered into a definitive Agreement and Plan of Merger on August 30, 2026, to acquire USI Advantage Corp. for $17 billion in cash, establishing a premier U.S. middle-market platform with expected annual synergies of $395 million and accretion to adjusted EPS in 2028, subject to regulatory approvals and expected to close in Q4 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-31
Item 7.01
SLB has signed an agreement to acquire Kelvion for approximately $3.4 billion in cash plus $0.7 billion of assumed debt (total ~$4.1 billion), representing a material acquisition that expands SLB's data center infrastructure business. The filing explicitly discloses entry into a material acquisition agreement with specific transaction terms, expected synergies of $120 million annually, and anticipated closing in H1 2027—all hallmarks of ma_activity under Item 1.01 or 2.01 of Form 8-K, disclosed here under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-31
EX-99.1
This exhibit is a press release announcing LexinFintech's unaudited financial results for the second quarter ended June 30, 2026. It discloses total operating revenue of RMB3,187 million (down 11.2% YoY), net income of RMB101 million (down 80.2% YoY), and key operational metrics including GMV, loan originations, and user growth. The document explicitly states "LexinFintech Holdings Ltd. Reports Second Quarter 2026 Unaudited Financial Results" and includes detailed financial highlights, operational metrics, and forward guidance, which are hallmarks of a quarterly earnings release.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-31
Item 5.02
Charles A. "Chuck" Parcher has assumed the role of President and Chief Executive Officer of Civista Bancshares, Inc. effective August 31, 2026, completing a previously announced leadership transition. While Dennis Shaffer's retirement as President and CEO is also disclosed, the principal action disclosed is Parcher's appointment to the CEO role, making this an exec_appointment event. The appointment of a new CEO is material to investors as it represents a significant change in leadership and strategic direction.
View raw filing on EDGAR →
6-K
M&A activity
confidence 75%
filed 2026-08-31
Exhibit 99.2 discloses a material acquisition of right-of-use assets by Chunghwa System Integration Co., Ltd. (a subsidiary of the registrant) from the parent company Chunghwa Telecom Co., Ltd. The transaction involves four real properties with a total transaction amount of NT$10,237,636 and right-of-use assets of NT$9,350,129, approved by the Board of Directors on 2026/08/31. While this is an intra-group transaction with a related party, the magnitude and formal board approval indicate materiality to investors assessing the registrant's asset base and related-party dealings.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 94%
filed 2026-08-31
Item 8.01
The company granted special incentive awards of performance stock units (PSUs) totaling approximately $100 million to five named executives, including CEO James R. Anderson ($50M), CFO Sherri Luther ($15M), CTO Julie Eng ($15M), Chief Strategy Officer Rob Beard ($15M), and Chief Supply Chain Officer Jeffrey Place ($5M). The awards are 100% performance-based with vesting tied to stock price milestones, relative TSR hurdles, and continued service through 2030, reflecting shareholder-aligned award design and termination provisions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-31
Item 8.01
Strategy Inc sold 4.5 million shares of Class A Common Stock under its at-the-market offering program during August 24–30, 2026, generating $602.8 million in net proceeds, with proceeds allocated to bitcoin purchases ($369.7 million), preferred stock repurchases, dividend funding, and cash reserves.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
Karyopharm announced submission of a supplemental New Drug Application (sNDA) to the FDA seeking Accelerated Approval for XPOVIO in combination with ruxolitinib for myelofibrosis, with a request for Priority Review. This is a material regulatory and operational milestone in the drug development and commercialization process that would affect a reasonable investor's assessment of the company's pipeline progress and commercial prospects. While the filing does not fit neatly into predefined categories like earnings, M&A, or litigation, it represents a significant operational/strategic development in the company's core business of bringing therapeutics to market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-31
The 6-K discloses that MGP, an indirect subsidiary, has submitted a renewal application to the Hong Kong Stock Exchange for a potential listing on the Main Board following the lapse of its original application. The filing incorporates by reference MGP's audited consolidated financial statements for the year ended December 31, 2025, and the six months ended June 30, 2026. This is a material operational and strategic development involving a potential capital markets transaction by a subsidiary, though the outcome remains uncertain pending regulatory approval and market conditions.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-31
Item 5.02
The filing discloses the Board's appointment of Dominic E. Dragisich as President and CEO effective August 31, 2026, and his concurrent appointment as a director. While the filing also mentions Patrick S. Pacious's resignation as former President and CEO, the principal disclosed action centers on Dragisich's appointment to the top executive role and the Board. The compensation details and amended severance agreement are ancillary to the core appointment event. This is material as it represents a permanent leadership transition for the company's chief executive.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-31
Item 7.01
The filing discloses a declaration of distributions to shareholders across three classes of common shares (Class S, I, and E) with specific per-share amounts ($0.13 gross, net of servicing fees), a record date of August 31, 2026, and a payment date of September 3, 2026. This is a routine but material dividend distribution disclosure typical of real estate investment trusts (REITs), which are required to distribute substantially all taxable income to shareholders.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-31
Item 7.01
PGIM Private Credit Fund declared regular distributions to shareholders across three share classes (S, D, and I) with per-share amounts of $0.16851, $0.18050, and $0.18550 respectively, with a record date of August 31, 2026 and payment date of approximately September 28, 2026.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-31
Item 8.01
The filing discloses a declaration of distributions to stockholders across four classes of common stock (Class I, D, T, and S), with gross distributions of $0.0770 per share and varying net distributions after stockholder servicing fees. The distributions are payable on or about September 3, 2026, and may be reinvested through the company's distribution reinvestment plan. This is a routine but material dividend declaration typical of a real estate investment trust (REIT).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-31
Item 7.01
The filing discloses a declaration of distributions to stockholders across multiple share classes (Class E, I, A-I, A-II, and T common stock) with specific per-share amounts ($0.04326 gross, varying net amounts after fees), a record date of August 31, 2026, and a payment date of approximately September 10, 2026. This is a routine but material dividend distribution disclosure typical of REITs, which are required to distribute substantially all taxable income to shareholders.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-31
Item 7.01
The filing discloses a declaration of distributions to shareholders across four classes of common shares (Class I, F, A, and E), with specific per-share amounts ranging from $0.1336 to $0.1546 gross, payable on September 9, 2026. This is a routine but material dividend distribution event typical of REITs and closed-end funds, which are required to distribute substantially all taxable income to shareholders.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-31
Item 7.01
The filing discloses a declaration of distributions to stockholders across multiple share classes, with specific per-share amounts ranging from $0.0749 to $0.1124 (gross), payable on or about September 21, 2026. This is a routine but material dividend declaration typical of a real estate income company, meeting the definition of dividend_distribution under the taxonomy.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-31
Item 1.01
Worthington Enterprises amended and restated its revolving credit facility on August 31, 2026, extending the maturity date from September 27, 2028 to August 31, 2031 while maintaining $500 million in aggregate commitments. This material amendment to an existing direct financial obligation represents a refinancing event material to investors assessing the company's liquidity and capital structure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-31
Item 3.01
The filing discloses that Nasdaq's Listing and Hearing Review Council affirmed a decision to delist Cambium Networks' ordinary shares from Nasdaq based on non-compliance with Listing Rule 5250(c)(1), with trading suspended since March 27, 2026. This is a definitive delisting determination (not merely a risk or warning), making it a material event that directly affects the registrant's market access and investor base. The company expects shares to trade on OTC Markets, but the loss of Nasdaq listing is a terminal market event.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-08-31
Item 1.01
Myers Industries completed the sale of its Myers Tire Supply (MTS) North American tire supply distribution division to Lion Equity Partners for $30 million. The transaction advances the company's 'Focused Transformation' strategy and strengthens its balance sheet.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-31
Item 8.01
PMV Pharmaceuticals announced updated interim Phase 2 clinical trial data for rezatapopt in ovarian cancer, showing a 46% overall response rate with a 10.0-month median duration of response, and disclosed FDA feedback supporting an NDA submission strategy for accelerated approval planned in Q1 2027. This is a material clinical and regulatory milestone for a precision oncology company's lead product candidate, but does not fit the specific event types (earnings, M&A, impairment, etc.); it is best classified as an operational milestone—the advancement of a key clinical program toward regulatory approval.
View raw filing on EDGAR →